Sexually Transmitted Diseases:
Emergence of Fluoroquinolone Resistance in Neisseria gonorrhoeae Isolates From Four Clinics in Three Regions of Kenya
Lagace-Wiens, Philippe R. S. MD*; Duncan, Sarah MD†,‡; Kimani, Joshua MBChB, MPH*,§; Thiong'o, Alexander DCM†; Shafi, Juma MSc§; McClelland, Scott MD, MPH¶; Sanders, Eduard J. MD, MPH, PhD†,‡; Zhanel, George PhD*; Muraguri, Nicholas MBChB, MPH‖; Mehta, Supriya D. MHS, PhD**
From the *University of Manitoba, Faculty of Medicine, Department of Medical Microbiology and Infectious Diseases, Winnipeg, MB, Canada; †Kenya Medical Research Institute (KEMRI), Kilifi, Kenya; ‡Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, Headington, United Kingdom; §University of Nairobi, Faculty of Medicine, Department of Medical Microbiology, Nairobi, Kenya; ¶University of Washington, School of Public Health, Seattle, WA; ‖National AIDS/STD Control Programme (NASCOP), Ministry of Public Health and Sanitation, Nairobi, Kenya; and **University of Illinois at Chicago, School of Public Health, Division of Epidemiology & Biostatistics, Chicago, IL
Kilifi: Salim Mwarumba, Benedict Mvera, and Susan Morpeth at the Kenya Medical Research Institute, Kilifi. The International AIDS Vaccine Initiative (IAVI) for supporting the high-risk cohort studies in Kilifi. This report was published with permission from KEMRI. Mombasa: National Institutes of Health (NIH) grants R01 AI58698 and P01 HD64915. The contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIH. Nairobi: Nancy Laing at the Health Sciences Centre, Winnipeg, Canada and Lisa Avery and Maryanne Crockett at the University of Manitoba, Jeckoniah N′dinya-Achola at the University of Nairobi. Kisumu: Ruth Murugu and Lawrence Agunda, Partners in Reproductive Health, Kisumu, Kenya.
Correspondence: Philippe R. S. Lagace-Wiens, MD, University of Manitoba Winnipeg, L4025-409 Taché Avenue, Winnipeg, Manitoba, Canada R2H 2A6. E-mail: firstname.lastname@example.org.
Received for publication July 4, 2011, and accepted December 28, 2011.
We have recently reported high levels of fluoroquinolone resistance in a single region of Kenya. In this article, we report high prevalence of fluoroquinolone resistance (53.2%) in Neisseria gonorrhoeae isolates from 4 clinics in 3 additional regions of Kenya. These findings highlight the need to change first-line treatment in these settings and the need to evaluate empirical management guidelines for treatment of gonococcal infection in Kenya.
Single-dose cephalosporin therapy (e.g., cefixime or ceftriaxone) is the recommended empirical treatment for gonococcal infections in most guidelines from industrialized countries.1,2 Furthermore, although the 2003 World Health Organization guidelines for the management of gonococcal infection include single-dose fluoroquinolone therapy unless prevalence of resistance exceeds an arbitrary threshold of 5%, recent publications by the World Health Organization have recognized that fluoroquinolone and multidrug resistant Neisseria gonorrhoeae are an emerging problem worldwide.3,4 Current treatment guidelines for syndromic management of urethritis and cervicitis in Kenya recommend single 800-mg dose norfloxacin for treatment of gonococcal infection (guidelines available at: http://collections.infocollections.org/whocountry/en/day/Jh4329e/). However, the prevalence of fluoroquinolone resistance in Kenya is largely unknown. Studies in the 1990s demonstrated universal susceptibility to fluoroquinolones.5,6 More recently, resistance has been documented in western Kenya and a restricted area of coastal Kenya.7,8 The purpose of this study was to determine the prevalence of fluoroquinolone resistance among isolates recovered from high-risk populations in 3 geographically distinct regions of Kenya.
Isolates were collected in 2009 and 2010 from 4 sites: Kisumu in western Kenya, the capital city Nairobi located on the principal highway connecting Mombasa and Kisumu, and Mombasa and Kilifi in coastal Kenya. Isolates were collected from high-risk individuals attending community or research clinics for medical care that included screening and management of sexually transmitted infections. Comparable data collection across sites included age, gender, human immunodeficiency virus status, sex work, and circumcision status of males. When clinically indicated, patients had urethral or cervical swabs collected that were cultured directly to modified Thayer–Martin medium. Cultures were incubated in 5% CO2 at 36°C up to 48 hours. Neisseria gonorrhoeae was identified using colonial morphology, Gram-stain, oxidase, and the superoxol test.
Susceptibility testing to cefixime, ceftriaxone, azithromycin, ciprofloxacin, and/or norfloxacin was performed using antibiotic disk diffusion or epilometry (E-test, BioMerieux, Marseille, France) on GC base agar (Oxoid, Basingstoke, United Kingdom) with 1% IsoVitalex (Oxoid) supplement. Antimicrobials studied and methods (disk or E-test) varied slightly at each site (Table 1). Quality control of the medium and antimicrobials was assured using N. gonorrhoeae strain ATCC 49226. Where available, interpretative breakpoints for disk diffusion and epsilometric assays were taken from the Clinical Laboratory Standards Institute (CLSI) document M100-S21. Because CLSI breakpoints were not available for azithromycin or norfloxacin, we used the breakpoints established by Knapp et al9 (norfloxacin) and Mehaffey et al10 (azithromycin). For these, the disk diffusion resistance breakpoints used in this study were as follows: azithromycin ≤24 mm and norfloxacin ≤32 mm, and for epsilometry and breakpoint for azithromycin, resistance was ≥2 μg/mL.
For statistical analysis and data presentation, isolates were considered either resistant or susceptible. Where applicable, isolates with intermediate susceptibilities (to ciprofloxacin only), according to CLSI breakpoints, were included in the susceptible group. Differences in regional resistance and association between demographic data and resistance were evaluated using Fisher exact test. Statistical analysis was performed using JMP version 9.0 (SAS, Cary, NC).
A total of 154 single isolates from 82 females and 72 males were tested: 64 from Kisumu, 44 from Nairobi, 29 from Mombasa, and 17 from Kilifi (Table 1). The 17 isolates from Kilifi have been previously reported,8 but are included here to demonstrate that the new findings are consistent with the earlier reported resistance rates. Susceptibility testing (Table 1) demonstrated that overall prevalence of resistance to fluoroquinolones was 53.2% (95% CI, 45.3%–61.8%). No significant difference in fluoroquinolone resistance was noted between the sites, or by patient characteristics. No resistance was observed for cefixime or ceftriaxone. Seven (6.5%) isolates had either azithromycin minimum inhibitory concentrations (MICs) of 0.5 μg/mL (n = 3) or inhibition zone diameters between 25 and 28 mm (n = 4).
Fluoroquinolone resistance in N. gonorrhoeae has been documented in North and South America, Europe, Southeast and South Asia, and Australia.8,11 Although fluoroquinolone therapy was considered first-line therapy for treatment of gonorrhea for a number of years, most national guidelines from industrialized countries now discourage their use because of high resistance rates.1,2 Increased MICs to cefixime and other cephalosporins (but still considered susceptible) have also been documented in a number of countries and prevalence appears to be increasing, particularly in Asia and the Western Pacific Region.2,11,12 Some of these isolates have been associated with treatment failures when single-dose oral cephalosporins are used to treat the infection.4,11 More recently, N. gonorrhoeae isolates with in vitro resistance to cephalosporins, including ceftriaxone, and treatment failures with ceftriaxone therapy have been reported.13,14 The potential emergence of multidrug resistant N. gonorrhoeae underscores the urgency of ongoing surveillance for timely detection and response.
Evaluation of antimicrobial resistance in N. gonorrhoeae isolates from Kenya has been sporadic over the past 40 years. Studies in the 1970s demonstrated high rates of penicillin resistance,15,16 and subsequent studies in the 1980s documented high rates of tetracycline resistance.6,17,18 Studies conducted in the 1990s revealed high rates of penicillin and tetracycline resistance with no fluoroquinolone resistance observed.5,6 No further antimicrobial susceptibility studies were published until 2009, when Mehta et al reported a high prevalence of fluoroquinolone resistance.7 The current study confirms the presence of fluoroquinolone resistance in selected high-risk populations in Kisumu, Nairobi, Mombasa, and Kilifi. The cause of emergence of resistance is unclear. Possible explanations include progressive accumulation of quinolone-resistant determining region mutations leading to resistance, or the spread of a drug resistance clone introduced into Kenya leading to more rapid emergence such as that which has recently occurred in South Africa.19 As with penicillin and tetracycline, it is likely that generalized overuse of fluoroquinolones has contributed to the emergence of resistance. Fortunately, the current study identified neither macrolide resistance nor increased cefixime MICs, suggesting that these agents should be clinically effective at the present time in the populations studied.
We identified 7 isolates with azithromycin MICs of 0.5 μg/mL or inhibition diameters between 25 and 28 mm. Although these isolates are considered susceptible by the breakpoints suggested by Mehaffey et al,10 isolates with an azithromycin MIC of 0.5 μg/mL are considered “intermediately” susceptible according to European breakpoints (available at: www.eucast.org). Furthermore, British susceptibility guidelines (available at: www.bsac.org.uk) indicate that isolates with azithromycin inhibition zone diameters <28 mm should be reported as resistant. Although the implication of finding such isolates in our study is unclear, treatment failures have been reported in patients treated with a 1 g dose of azithromycin, who had been infected with such isolates.20
Our study had limitations. The isolates studied do not represent a random sample. Rather, specimens were collected from individuals attending research clinics. Considering the estimated 2% to 3% prevalence rate of gonorrhea in sub-Saharan Africa,12 our numbers constitute a very small proportion of the total number of cases in Kenya. In 3 sites, patients were nearly exclusively high-risk sex workers. Participants in these cohorts may have been exposed to higher rates of sexually transmitted infection screening and treatment than the general population, which may have influenced the proportion of isolates with fluoroquinolone resistance. As such, these results may not reflect the resistance rates in the general population. Nonetheless, the findings remain striking, and raise concern that widespread resistance to fluoroquinolones could already be present in Kenya. The high resistance rates observed in the symptomatic men without defined risk factors from Kisumu also suggest that high resistance rates may extend beyond high-risk cohorts.
The high level of resistance to fluoroquinolones in N. gonorrhoeae isolates from a range of higher risk populations in different regions of Kenya is worrisome. These data suggest that recommended regimen for first-line treatment of gonorrhea should be changed to cefixime or a recognized alternative cephalosporin in high-risk populations. All participating clinics are now using cefixime to treat gonorrhea. Careful consideration should be given to changing the recommended regimen in other populations as well. If fluoroquinolones are used as first-line treatment, either because of lack of data or unavailability of alternatives, clinicians and patients should be aware of the risk for resistance and treatment failure. Revision of the national treatment guidelines should be considered and changes guided by collection of additional data on isolates from a sampling of all regions in Kenya. Ongoing surveillance will be crucial to follow the rates of fluoroquinolone resistance in the general population, characterize possible geographic variations in a larger sample, and monitor susceptibility to cephalosporins and azithromycin.
1. Tapsall JW. What management is there for gonorrhea in the postquinolone era? Sex Transm Dis 2006; 33:8–10.
2. Workowski KA, Berman S. Sexually transmitted diseases treatment guidelines, 2010. MMWR Recomm Rep 2010; 59(RR-12):1–110.
4. Emergence of multi-drug resistant Neisseria gonorrhoeae
—Threat of global rise in untreatable sexually transmitted infections. World Health Organization Department of Reproductive Health and Research, 2011. Available at: http://whqlibdoc.who.int/hq/2011/WHO_RHR_11.14_eng.pdf
. Accessed December 25, 2011
5. Claeys G, Taelman H, Gichangi P, et al.. Antimicrobial susceptibility of Neisseria gonorrhoeae
isolates from men with urethritis in Kenya. Sex Transm Infect 1998; 74:294–295.
6. Slaney L, Chubb H, Mohammed Z, et al.. In vitro activity of meropenem against Neisseria gonorrhoeae
, Haemophilus influenzae
and H. ducreyi
from Canada and Kenya. J Antimicrob Chemother 1989; 24(suppl A):183–186.
8. Duncan S, Thiong'o AN, Macharia M, et al.. High prevalence of quinolone resistance in Neisseria gonorrhoeae
in coastal Kenya. Sex Transm Infect 2011; 87:231.
9. Knapp JS, Hale JA, Neal SW, et al.. Proposed criteria for interpretation of susceptibilities of strains of Neisseria gonorrhoeae
to ciprofloxacin, ofloxacin, enoxacin, lomefloxacin, and norfloxacin. Antimicrob Agents Chemother 1995; 39:2442–2445.
10. Mehaffey PC, Putnam SD, Barrett MS, et al.. Evaluation of in vitro spectra of activity of azithromycin, clarithromycin, and erythromycin tested against strains of Neisseria gonorrhoeae
by reference agar dilution, disk diffusion, and E-test methods. J Clin Microbiol 1996; 34:479–481.
11. Deguchi T, Nakane K, Yasuda M, et al.. Emergence and spread of drug resistant Neisseria gonorrhoeae
. J Urol 2010; 184:851–858; quiz 1235.
12. Mehta SD, Maclean I, Ndinya-Achola JO, et al.. Emergence of quinolone resistance and cephalosporin MIC creep in Neisseria gonorrhoeae
isolates from a cohort of young men in Kisumu, Kenya, 2002 to 2009. Antimicrob Agents Chemother 2011; 55:3882–3888.
13. Tapsall J, Read P, Carmody C, et al.. Two cases of failed ceftriaxone treatment in pharyngeal gonorrhoea verified by molecular microbiological methods. J Med Microbiol 2009; 58(Pt 5):683–687.
14. Ohnishi M, Saika T, Hoshina S, et al.. Ceftriaxone-resistant Neisseria gonorrhoeae
. Japan Emerg Infect Dis 2011; 17:148–149.
15. Verhagen AR, Van der Ham M, Heimans AL, et al.. Diminished antibiotic sensitivity of Neisseria gonorrhoeae
in urban and rural areas in Kenya. Bull World Health Organ 1971; 45:707–717.
16. Perine PL, Biddle JW, Nsanze H, et al.. Gonococcal drug resistance and treatment of gonorrhoea in Nairobi. East Afr Med J 1980; 57:238–246.
17. Brunham RC, Fransen L, Plummer F, et al.. Antimicrobial susceptibility testing and phenotyping of Neisseria gonorrhoeae
isolated from patients with ophthalmia neonatorum in Nairobi, Kenya. Antimicrob Agents Chemother 1985; 28:393–396.
18. van Hall MA, Petit PL, van Hall HN, et al.. Prevalence of resistance of N. gonorrhoeae
to penicillin and three other antibiotics in a rural area in Kenya. East Afr Med J 1991; 68:853–859.
19. Lewis DA, Scott L, Slabbert M, et al.. Escalation in the relative prevalence of ciprofloxacin-resistant gonorrhoea among men with urethral discharge in two South African cities: Association with HIV seropositivity. Sex Transm Infect 2008; 84:352–355.
20. Young H, Moyes A, McMillan A. Azithromycin and erythromycin resistant Neisseria gonorrhoeae
following treatment with azithromycin. Int J STD AIDS 1997; 8:299–302.
© Copyright 2012 American Sexually Transmitted Diseases Association